Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer

類似資料

• A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay
  著者:: Landi, Lorenza, 等
  出版事項: (2017)
• Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?
  著者:: Ruiz, Jimmy, 等
  出版事項: (2015)
• Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
  著者:: Stasi, Irene, 等
  出版事項: (2014)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  著者:: Ourania Romanidou, 等
  出版事項: (2016-05-01)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  著者:: Romanidou, Ourania, 等
  出版事項: (2016)